Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors
about
Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancerHydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer.Rationale for targeting fibroblast growth factor receptor signaling in breast cancerDNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contaminationFGFR-1 amplification in metastatic lymph-nodal and haematogenous lobular breast carcinoma.Late recurrence of breast carcinoma metastasis to the hypopharynx: a case reportInhibition of BET proteins impairs estrogen-mediated growth and transcription in breast cancers by pausing RNA polymerase advancement.Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look?Targeting fibroblast growth factor receptor in breast cancer: a promise or a pitfall?New Coumarin Derivatives as Anti-Breast and Anti-Cervical Cancer Agents Targeting VEGFR-2 and p38α MAPK.A FGFR1 inhibitor patent review: progress since 2010.Endometrial Carcinoma: Specific Targeted Pathways.VEGFR-2 inhibitors and apoptosis inducers: synthesis and molecular design of new benzo[g]quinazolin bearing benzenesulfonamide moiety.Antiangiogenic Effects of VH02, a Novel Urea Derivative: In Vitro and in Vivo Studies.
P2860
Q26825584-23EAF04A-2968-4CF5-8AD5-7AA5350F992CQ33813981-C2E3CB81-1244-4629-9307-C95AA3C48CC9Q35131258-61763F4F-62A5-46E9-A6DE-2EDEF0E807DCQ36204976-C1CD93E8-A15E-4E0B-88DC-EE6101D9CD13Q36524946-62E6B7DA-0DF9-4A7E-BC28-129C66C48AE6Q36894951-BB65DC8B-CD45-4284-A0D1-A9FC79D020EFQ37234543-C9CC2A2E-43C7-4743-974C-F0EF6CE01111Q37921797-E1FC9ABF-A76A-4DED-BC16-D9FCFB530266Q38212165-AFF0B8B2-86CE-4CA3-93C6-D5722E44B02EQ38695524-A38C0E95-4626-4258-9CAC-0AD496C51462Q38782612-EB267434-0208-42DC-8079-80150CE16F80Q39026766-D725C8B6-9F67-4F52-AF9C-67F1E5A6C9BDQ46529985-9142AD86-CE75-4E86-AF98-730787824A72Q52675240-E162F9EC-59E8-4762-8B5C-5E1D624BCB82
P2860
Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitors
description
2010 nî lūn-bûn
@nan
2010 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մարտին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@ast
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@en
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@nl
type
label
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@ast
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@en
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@nl
prefLabel
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@ast
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@en
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@nl
P2093
P2860
P1476
Experimental treatment of oest ...... ion of angiogenesis inhibitors
@en
P2093
Andres J Klein-Szanto
Eric A Ross
Helen R Kim
Jennifer R Pyle
Joseph Fargnoli
Roshani R Patel
Salewa Oseni
Surojeet Sengupta
P2860
P304
P356
10.1016/J.EJCA.2010.02.018
P577
2010-03-18T00:00:00Z